Sparks, J
However, 7 cross sectional studies examining acute effects of the GLP-1-based therapies 37,38,39,40,41,42,43 found a significant increase in % FMD following GLP-1-based interventions (mean difference in the changes from baseline: 2.58 [1.68, 3.53] %
This is the most common thing patients say in their first month on GLP-1 therapy
The logic: if they can help people stay on effective medications, they reduce long-term risk
Some people also notice an improvement in their overall sense of well-being and a reduction in symptoms associated with deficiency, such as tingling or numbness in the extremities
However, cost calculations get more complex when considering CagriSema protocols